246 results about "Red blood cell" patented technology

The present invention relates to systems and methods for optimizing plasma collection volume. A plasma withdrawal system and a method for operating a plasma withdrawal system are provided by which the volume / weight of the anticoagulated plasma collected is optimized. In one example, a nomogram is provided that utilizes the donor hematocrit to calculate the volume / weight of raw plasma within a plasma product having a maximum volume allowed by the FDA nomogram. In a plasma withdrawal process having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the increasing hematocrit of the donor, resulting in a greater total volume of plasma product to be collected during the plasma withdrawal process.

A blood separation device includes a pump system, a separator, and a controller. The controller is programmed to execute a blood separation procedure including a red blood cell collection stage in which blood is conveyed into the separator, red blood cells are separated from the blood in the separator, and the separated red blood cells are conveyed from the separator into a collection container. The red blood cell collection stage is ended when a target volume of blood has been separated in the separator. The controller then determines a percentage of the red blood cells from the target volume of blood that have been collected in the collection container based on the volume of red blood cells and the hematocrit of the fluid in the collection container, a volumetric flow rate of pure red blood cells in the blood conveyed into the separator, and the procedure time.

The rejection monitoring device comprises a bottom cylinder and a monitoring assembly, the monitoring assembly comprises a liquid inlet pipe connected to the outer side of the bottom cylinder, a partition plate is arranged on the outer side of a middle line of a connector of the liquid inlet pipe and the bottom cylinder, a pair of guide plates is arranged at the bottom end of the partition plate, and liquid guide holes are vertically formed in the two guide plates; a motor is arranged on the inner bottom wall of the bottom cylinder, the output shaft end of the motor is coaxially connected with a tray, a plurality of pairs of analysis cylinders are uniformly arranged on the tray, and the bottom ends of the two liquid guide holes are respectively aligned with any pair of analysis cylinders in the vertical direction; the urine and blood states of a patient can be regularly detected through the arranged monitoring assembly, the operation difficulty of medical staff is reduced, meanwhile, the sampling time and the time difference for obtaining the detection result can be shortened, and then the monitoring effect of the monitoring assembly is improved; red blood cells and proteins or other biochemical indexes in urine of a patient can be detected through the detection agent filled in the analysis cylinder.

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.

Quinones for use in therapeutic recovery, normalization and / or improvement of ATP in mitochondrial deficient cells, such as red blood cells, are disclosed. Particular examples are use in the treatment of erythrocystic diseases, especially in the treatment of erythrocyte metabolic defects, such as erythrocyte glycolysis defects. This treatment increases ATP in non-mitochondrial cells. Thus, the present invention relates to quinones for use in the treatment of diseases or conditions associated with or caused by a glycolytic deficiency in red blood cells.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke. By constructing a mouse model of heatstroke-induced myocardial injury and observing indicators such as rectal temperature, blood routine tests, blood biochemistry, oxidative stress, and cardiac function, this invention found that lemon balm glycosides can significantly reduce the increase in rectal temperature caused by heatstroke in mice, increase the content of red blood cells and albumin in plasma, and reduce the level of oxidative stress in myocardial cells. Therefore, the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke is proposed.

A system and method of isolating extracellular vesicles. The method includes loading one or more of blood or bone marrow into an input port of a concentration system and centrifuging one or more of the blood or bone marrow to separate one or more of red blood cells, platelet poor plasma, or platelet rich plasma / bone marrow concentrate fractions via a centrifuge device. The method further includes pumping one or more of bone marrow / platelet rich plasma fractions and platelet poor plasma fractions into a receptacle of the concentration system and adding a concentrated aqueous two-phase solution to one or more of the bone marrow concentrate / platelet rich plasma fractions and platelet poor plasma fractions. The method also includes drawing the concentrated aqueous two-phase solution and one or more of the bone marrow concentrate / platelet rich plasma fractions or platelet poor plasma fractions back into the centrifuge device to isolate one or more of extracellular vesicles and platelet rich plasma / bone marrow concentrate fractions.

This invention relates to a method and application for enriching circulating tumor cells (CTCs) based on ambient temperature mechanical perfusion technology, belonging to the field of biomedical technology. The method comprises the following steps: flushing the liver resected during liver transplantation via the portal vein and hepatic artery, connecting it to an ambient temperature mechanical perfusion loop, and performing in vitro perfusion using simulated blood perfusion fluid; when perfusion exceeds 2 hours and the lactate content drops to <5 mmol / L, collecting the simulated blood perfusion fluid; and sequentially subjecting the simulated blood perfusion fluid to centrifugation, red blood cell removal, and white blood cell removal to obtain enriched circulating tumor cells (CTCs) for liver cancer. A human liver cancer ex vivo organ perfusion model is constructed using NMP technology to fully recreate the tumor microenvironment and CTC generation process, and the large volume of perfusion fluid is processed to achieve efficient enrichment of CTCs.

The present disclosure describes anti-inflammatory properties of red blood cell extracellular vesicles, e.g., as mediated by heme, hemoglobin and / or phosphatidylserine content. The present disclosure describes technologies useful for the treatment of inflammatory diseases, disorders, or conditions (e.g., atherosclerosis).

The application belongs to the technical field of antibacterial medicine, and particularly relates to a cinnamaldehyde-modified polypyridine ruthenium complex for inhibiting hemolysis, a preparation method and application thereof. The cinnamaldehyde-modified polypyridine ruthenium complex has a structure as shown in formula I. 1 , formula I 2 or formula I 3 The cinnamaldehyde-modified polypyridine ruthenium complex can effectively reduce the hemolysis of red blood cells caused by toxins released by Staphylococcus aureus, and the ruthenium complex does not induce the drug resistance of bacteria, and can significantly increase the sensitivity of Staphylococcus aureus to aminoglycoside antibiotics.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition for promoting blood circulation to remove meridian obstruction and a preparation method and application thereof. The traditional Chinese medicine composition for promoting blood circulation to remove meridian obstruction is prepared from the following raw materials in parts by weight: 15 to 25 parts of herba taxilli, 18 to 22 parts of semen cuscutae, 8 to 15 parts of radix angelicae sinensis, 3 to 6 parts of radix salviae miltiorrhizae, 18 to 22 parts of radix dipsaci, 8 to 15 parts of herba leonuri, 12 to 18 parts of radix paeoniae alba, 25 to 35 parts of rhizoma dioscoreae, 6 to 12 parts of rhizoma chuanxiong, 3 to 8 parts of radix aucklandiae, 6 to 12 parts of fructus nelumbinis, 10 to 15 parts of radix scutellariae and 12 to 20 parts of roasted rhizoma atractylodis macrocephalae. The traditional Chinese medicine composition obtained through the composition, the dosage and the proportion of the components can remarkably reduce the whole blood viscosity, hematocrit and plasma viscosity of a rat with a blood stasis syndrome, can remarkably reduce the twisting frequency of an experimental dysmenorrhea model rat, has the effects of activating blood, resisting inflammation, dredging collaterals and relieving pain, and has the effect superior to that of each pair of components.

The present application relates to the technical field of image processing, and provides a blood flow rate measurement method, system, device, product and medium based on images, comprising: selecting a capillary to be measured; selecting a first position and a second position on the capillary to be measured, and measuring horizontal and vertical orientation differences; obtaining a first number of red blood cell images and a second number of red blood cell images, respectively, and calculating a red blood cell spacing difference through the first and second numbers of red blood cell images; constructing a first motion equation and a second motion equation, and obtaining a red blood cell velocity relationship through solving the first and second motion equations; constructing a differential relationship of red blood cell acceleration, substituting the red blood cell velocity relationship and the second motion equation into the differential relationship to obtain a target differential equation, and solving the target differential equation to obtain a blood flow rate. The present application can conveniently measure the blood flow rate.

The present disclosure relates to a novel drug delivery system, which comprises a lipid particle and a modified red blood cell. The present disclosure also relates to preparation of the drug delivery system and therapeutic use thereof.

This invention belongs to the field of traditional Chinese medicine, specifically relating to a ginseng and licorice root formula for treating renal hematuria, its preparation method, and its application. The ginseng and licorice root formula for treating renal hematuria of this invention comprises the following raw materials in parts by weight: 5-15 parts of Codonopsis pilosula, 15-30 parts of Rehmannia glutinosa, 5-15 parts of Ligustrum lucidum, 5-15 parts of Eclipta prostrata, 5-15 parts of Imperata cylindrica, 5-15 parts of Rubia cordifolia, 5-15 parts of Cirsium japonicum, 5-15 parts of Taraxacum mongolicum, 5-8 parts of Prunus persica, and 3-5 parts of Glycyrrhiza uralensis. Clinical trials have shown that the ginseng and licorice root formula for treating renal hematuria of this invention not only reduces urinary red blood cells but also improves traditional Chinese medicine clinical symptoms such as lower back and knee weakness, fixed or stabbing lower back pain, pale complexion, fatigue, dry mouth, bitter taste, sore throat, rough skin, and poor appetite. It has good therapeutic effects, reliable safety, and can significantly improve the treatment efficacy of chronic nephritis syndrome.

The application discloses a red blood cell alloantibody specificity analysis method, and aims at the defects in the prior art that a large amount of manual experience and subjective judgment are relied on to exclude positive antigens according to the results of non-agglutination of samples to be detected and cells, and scientific methods such as statistics are lacked to verify the reliability of detection results, and provides a red blood cell alloantibody specificity analysis method. According to the expression of red blood cell antigens of spectrum cells / anti-screen cells and the agglutination results of patient serum / plasma, the red blood cell alloantibody specificity is analyzed by using programmed analysis logic and statistical result analysis.

The application provides a stem cell collector, which comprises a body and two extrusion devices, the body has two inner cavities, a front side wall of the body is formed with two extrusion surfaces, the extrusion surfaces are provided with openings in communication with the inner cavities, and the two extrusion devices are arranged on the body and correspond to one extrusion surface respectively. The extrusion device comprises an extrusion plate, a first moving assembly, a partition plate, a second moving assembly, an extrusion block, a third moving assembly and a driving mechanism. The stem cell collector can automatically extrude a blood bag, facilitates the collection of a solution containing a plasma layer, a white blood cell and platelet layer and a small part of a red blood cell layer, reduces the mixing of the red blood cell layer, improves the collection efficiency and brings convenience for the collection of stem cells.

An agent is for inhibiting glucose uptake into red blood cells and a blood collection tube suppresses glucose concentration decrease. The agent for inhibiting glucose uptake into red blood cells includes inosine as an active ingredient. The inhibition agent can be used for suppressing a decrease in glucose concentration of whole blood collected in a blood collection tube. The blood collection tube includes inosine in an internal space. The blood collection tube can be used to measure glucose concentration in blood. The blood collection tube can further include a glycolysis inhibitor.

The invention discloses a hematuria analysis method, device and equipment based on artificial intelligence and a storage medium. The method comprises the following steps: acquiring a urine visible component graph of urine to be analyzed and an interference state of the urine to be analyzed; selecting a hematuria analysis network model corresponding to the interference state from a preset corresponding relation set of the interference state and the hematuria analysis network model; the urine visible component graph is input into the hematuria analysis network model, the number of red blood cells corresponding to the to-be-analyzed urine is determined through the urine visible component graph, the hematuria category corresponding to the to-be-analyzed urine is determined based on the number of red blood cells, and the hematuria category comprises pseudo hematuria or true hematuria. According to the interference state of the to-be-analyzed urine, by constructing a plurality of corresponding hematuria analysis network models, misjudgment of the red blood cells in the to-be-analyzed urine can be reduced, accurate counting of the red blood cells is achieved, and therefore the accuracy of true hematuria detection is improved.

The present invention relates to a method and apparatus for determining the activity of clotting factors in diluted capillary whole blood, citrated whole blood and citrated plasma. The invention also includes the detection of hemoglobin content in the whole blood sample to correct for clotting time so that the clotting time values are not affected by hemoglobin and hematocrit.

Provided herein are compounds and compositions thereof for activating nuclear factor erythroid 2-related factor 2 (Nrf2) for treating red blood cell diseases and inflammatory diseases.

There remains a need for effective therapeutic agents for the treatment of TGFβ superfamily-associated disorders. [Solution] Polypeptides comprising an activin receptor type IIB (ActRIIB) ectodomain (ECD) variant are provided. In some embodiments, the polypeptides of the present disclosure comprise an ActRIIB-ECD variant fused to an Fc domain portion. The present disclosure also provides pharmaceutical compositions and methods using the polypeptides to treat diseases and conditions associated with TGF-β superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (e.g., anemia).

The invention belongs to the technical field of blood bag plasma separation, and particularly relates to an integrated device with blood bag plasma separation and heat seal tube sealing functions. The integrated device comprises a workbench, a clamping groove is formed in the surface of the workbench, a clamping bottom plate is fixedly installed on the inner wall of the clamping groove, and two connecting sleeves are fixedly installed on the inner wall of the workbench; after the blood bag is separated, the clamping bottom plate and the clamping side plate are separated at first, then the clamping side plate is separated from the clamping bottom plate through a connecting plate and a power rod, then the blood bag can be placed on one side of the clamping bottom plate, the blood bag is connected with a liquid storage bag through a liquid outlet pipe, and then the clamping side plate moves towards one side of the clamping bottom plate; and then the clamping side plate can automatically extrude the blood bag located on one side of the clamping bottom plate, plasma located on the upper layer in the blood bag is discharged from the liquid outlet pipe, then the liquid outlet pipe is sealed through the heat sealing device, automatic extrusion separation and heat sealing packaging work of the plasma and red blood cells in the blood bag is completed, the automation degree is improved, and the working efficiency is improved.

The invention relates to the technical field of medicines, in particular to application of huperzine A in treatment of beta-thalassemia. It is found for the first time that the anti-Alzheimer disease drug huperzine A can be directly combined with gamma-globin to inhibit degradation of gamma-globin through a ubiquitin-proteasome pathway, so that the stability of gamma-globin and the fetal hemoglobin level are improved; the abnormal erythropoiesis and hemolysis phenotype of the beta-thalassemia are improved under the condition of not changing the mRNA expression. Animal experiments show that huperzine A obviously improves hematocrit and the number of red blood cells, reduces the size distribution width of the red blood cells and the proportion of reticulocytes, relieves oxidative stress, hemolysis, splenomegaly and iron overload, and has no obvious liver and kidney toxicity. The invention creatively provides a new strategy for improving HbF by regulating and controlling protein homeostasis instead of transcriptional up-regulation, and provides a new drug action mechanism and application direction for treatment of beta-thalassemia and other hemoglobin diseases.

The application discloses a kit for predicting the curative effect of immunotherapy on prostate cancer patients, which comprises reagent A, reagent B, reagent C, reagent D, reagent E and reagent F; the reagent A is a PBS buffer solution; the reagent B is a lymphocyte separation medium; the reagent C is a red blood cell lysis solution; the reagent D is a cell surface CD3 flow antibody; the reagent E is a cell surface CD19 flow antibody; and the reagent F is a 1% polyformaldehyde solution in terms of mass percentage concentration. The application further discloses an application method of the kit, which comprises the following steps: collecting venous blood of prostate cancer patients; extracting peripheral blood mononuclear cells (PBMC) in the venous blood of the prostate cancer patients; incubating the flow antibody; and performing flow cytometry analysis. The kit and the application thereof are simple and fast, non-invasive, repeatable, low in cost and short in detection time.

The application discloses a sample analysis method, a sample analysis system and a readable storage medium, and relates to the technical field of medical apparatuses.The method comprises the following steps: obtaining the red blood cell concentration, the normal red blood cell proportion and the abnormal red blood cell proportion of at least one sample, wherein the normal red blood cells and the abnormal red blood cells respectively refer to red blood cells meeting a preset shape standard and red blood cells not meeting the preset shape standard; determining the red blood cell detection result of the sample according to the red blood cell concentration, the normal red blood cell proportion, the abnormal red blood cell proportion, a preset concentration threshold and / or a preset shape proportion threshold; and displaying the red blood cell detection result of the sample on a visual window.The technical scheme can enable a user to browse the red blood cell detection result determined according to the predefined concentration threshold and shape proportion threshold, improve the flexibility of visual display of the red blood cell detection result, and meet the needs of the user in more areas and scenes.

The invention provides a melittin polymer, which is formed by at least connecting disulfide bonds between two melittin variant molecules after a melittin variant is formed by mutating alanine at the fourth site of an amino acid sequence of a melittin monomer into cysteine and mutating isoleucine at the twentieth site into cysteine in the amino acid sequence of the melittin monomer. The preparation method of the melittin polymer comprises the following steps: obtaining a melittin variant through escherichia coli recombinant expression, and purifying and oxidizing the obtained melittin variant through a nickel column to obtain the melittin polymer, and carrying out gel filtration chromatography on the obtained melittin polymer to obtain the purified melittin polymer. The invention also provides an application of the melittin polymer, and the melittin polymer is used for preparing antibacterial drugs or antibacterial feed additives. The prepared melittin polymer can effectively reduce the toxicity to red blood cells, has relatively strong environmental responsiveness and stability, and can effectively prolong the antibacterial aging.

The present application relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for reducing adverse reactions after radiotherapy and chemotherapy of tumor patients and a preparation method thereof, comprising the following components in parts by weight: Radix Bupleuri 6-9 parts, Radix Paeoniae Alba 6-9 parts, Rhizoma Atractylodis Macrocephalae 6-9 parts, Poria 6-9 parts, Angelica sinensis 6-9 parts, Zingiber officinale 3 parts, Radix Rehmanniae Recens 3-6 parts, Gardenia 3-6 parts, Radix Paeoniae Rubra 3-6 parts, Radix Paeoniae Alba 12-20 parts, Rhizoma Chuanxiong 6 parts, and Radix Glycyrrhizae 3-6 parts; the traditional Chinese medicine composition can improve the spirit and movement state of mice, and the weight and food intake of mice are obviously increased, the number of dead mice is significantly reduced, and the tumor volume and weight of mice are significantly reduced; the spleen and thymus indexes, the number of white blood cells, red blood cells and platelets in peripheral blood, and the hemoglobin content are all significantly increased; the number of bone marrow cells and the CD4 + T / CD8 + T cell ratio in peripheral blood are all significantly increased; when applied to clinical patients, the traditional Chinese medicine composition can reduce adverse reactions after radiotherapy and chemotherapy of tumor patients, and has a broad application prospect.

The invention is applicable to the technical field of PCR (polymerase chain reaction) detection, and provides an eperythrozoonosis and babesiosis dual rapid detection kit and application thereof, and an eperythrozoon and babesiosis specific primer group, which comprises an eperythrozoon upstream primer, an eperythrozoon downstream primer, a babesiosis upstream primer and a babesiosis downstream primer, the nucleotide sequence of the upstream primer of the eperythrozoon is as shown in SEQ ID No. 1, and the nucleotide sequence of the downstream primer of the eperythrozoon is as shown in SEQ ID No. 2; the nucleotide sequence of the upstream primer of the babesia is as shown in SEQ ID No.3, and the nucleotide sequence of the downstream primer of the babesia is as shown in SEQ ID No.4. The PCR primers are designed for specific gene areas of the two pathogens, optimization is carried out on targeting sites and sequences, and the PCR primers are remarkably different from conventional primers, have higher specificity and amplification pertinence and solve the problems that an existing detection method is poor in specificity and low in sensitivity and cannot synchronously detect the two pathogens. And rapid and accurate diagnosis of single or mixed infection of eperythrozoon and babesia is realized.

This invention relates to the field of drug concentration detection technology, specifically to a rapid method for detecting blood drug concentrations in emergency patients. The method involves collecting time-series biochemical reaction signals from whole blood samples within a fixed time window, obtaining a net signal sequence after benchmark removal; constructing a baseline linear reference sequence connecting the zero point and the endpoint using a preset cutoff time endpoint value; calculating the vertical difference between the net signal and this reference to determine the time of maximum deviation; and finally, using the endpoint value and the time of maximum deviation as a two-dimensional index to query a preset compensation table and output the drug concentration corrected for hematocrit. This method utilizes reaction kinetic morphology characteristics to decouple the diffusion hindrance effect caused by high hematocrit, avoiding false low concentration results due to incomplete reaction equilibrium. It significantly improves the accuracy and reliability of blood drug concentration detection in emergency settings under conditions of no centrifugation and direct whole blood measurement.

The invention belongs to the technical field of clinical medicine, and relates to a method for extracting autologous platelet-rich plasma, which comprises the following steps of: adding an anticoagulant into an injector I in advance, then extracting autoblood, uniformly mixing for 3-4 times back and forth by virtue of an injector II, then centrifuging for 10 minutes at the speed of 1,500 revolutions per minute, sucking the platelet-rich plasma in the injector I by virtue of an injector III, and extracting the platelet-rich plasma in the injector II by virtue of an injector III. And centrifuging again, and discarding the supernatant by using an injector IV to obtain a high-concentration PRP finished product. According to the extraction method, in the extraction process, blood is uniformly mixed for 3-4 times back and forth between an injector I and an injector II, and the blood is centrifuged for 10 minutes at the speed of 1500 r / min in the first centrifugation process, so that the platelet concentration in the finally extracted PRP is remarkably improved compared with the platelet concentration in peripheral blood; the red blood cells reach the quality control target, the white blood cells are obviously reduced, and a set of standardized autologous platelet-rich plasma clinical extraction method which is simple in extraction device, low in consumable cost, simple to operate and high in extraction concentration is formed.